TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02783664

Intervention type: OTHER
Intervention: Questionnaires to Evaluate Anxiety Related to Genetic Testing
Description: A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total.
Study: NCT02863471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
Study: NCT02938260

Intervention type: DRUG
Intervention: Metoprolol vs Diltiazem

Intervention type: DRUG
Intervention: Metoprolol vs Diltiazem
Study: NCT00898898

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study: NCT02029846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: traditional drugs only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incretin-Based Treatment
Description: incretin-based drugs
Study: NCT03060460

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound guided sheath insertion
Description: ultrasound is used routinely for sheath insertion
Study: NCT01689337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330)
Description: Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330)
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study: NCT02389608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Study: NCT03169504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug
Description: Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture plus conventional drug
Description: Both acupuncture and conventional drug will be used for 12 weeks treatment.
Study: NCT02970474

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Bolus
Description: Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Printed Bolus
Description: The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
Study: NCT02391454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RunKeeper App
Description: Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study: NCT00781287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-drug anti-HIV therapy
Description: 3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-drug anti-HIV therapy
Description: 3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg BID PO
Study: NCT01827618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Study: NCT02034370

Intervention type: DEVICE
Intervention: Lung-function spirometry test
Description: 5 minute lung function test performed once preoperatively and once postoperatively

Intervention type: DEVICE
Intervention: Overnight sleep test
Description: Somte sleep monitor to be worn two nights before and the night of surgery.
Study: NCT02370810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based internet-intervention for tinnitus
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-based internet-intervention for tinnitus
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
Study: NCT00584649

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electrophysiology study and radiofrequency ablation
Description: stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
Study: NCT01418989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra] Syringe
Description: Single dose administration with pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra] auto-injector
Description: Single dose administration with auto-injector
Study: NCT02518490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire Lens
Description: Each subject will be randomized to wear the test lens on one eye and control lens on one eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
Study: NCT02086123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: Bupivacaine + Fentanyl

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Analgesia (Intravenous)
Description: Dilaudid 0.2 -0.4 mg IV every 3 hours
Study: NCT04256629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized subjects will receive oral dose of verinurad

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
Study: NCT02738944

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry Collaborative Care
Description: The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry Enhanced Referral
Description: The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home.
Study: NCT04100668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensifree's Alpha sensor
Description: RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrow® arterial catheterization kit (Teleflex)
Description: Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor
Description: PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
Study: NCT04882995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyillium fiber
Description: Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
Study: NCT03753659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio Frequency Ablation (RFA)
Description: Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolisation (TACE)
Description: According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
Study: NCT00477334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: oral; two 500 mg tablets twice a day; single day treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; two tablets twice a day; single day treatment
Study: NCT01452659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT05402930

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiomammography
Description: Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR.
Study: NCT01170611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACEMAKER SYMPHONY 2550
Study: NCT02541123

Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.

Intervention type: OTHER
Intervention: Blood draw
Description: Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
Study: NCT03562650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Fading
Description: Participants are asked to fade their three most common safety behaviors associated with their social anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered
Description: Participants are asked to try to increase their focus on the present.
Study: NCT01293305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 capsule three times daily, preferably in the same period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chondroitin sulfate + Glucosamine sulfate
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.
Study: NCT03234985

Intervention type: BIOLOGICAL
Intervention: Biological analyses
Description: Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
Study: NCT03536143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical beremagene geperpavec
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study: NCT02115516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (Placebo)